Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

VILDAGLIPTINA DIAGONALIS 50 MG COMPRIMIDOS EFG - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/VILDAGLIPTINA DIAGONALIS 50 MG COMPRIMIDOS EFG

Approved

STANDARD

VILDAGLIPTINA DIAGONALIS 50 MG COMPRIMIDOS EFG

Galenicum Health S.L.U.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Jul 21, 2022
Approval ID: 7e48534acbd8201d
Company: Galenicum Health S.L.U.
Type: Standard

Approval Details

Approval Id: 7e48534acbd8201d
Drug Cima Aemps Name: VILDAGLIPTINA DIAGONALIS 50 MG COMPRIMIDOS EFG
Register Number: 87852
Holder Company Name: Galenicum Health S.L.U.
Marketing Company Name: Galenicum Health S.L.U.
Authorization Date: 2022-07-21
Dosage Form: COMPRIMIDO
Dose: 50 mg
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: No
Company Name: Galenicum Health S.L.U.

Active Ingredients

VILDAGLIPTINA

50 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Jul 21, 2022

Approval ID

7e48534acbd8201d

Type

Standard

Back to CIMA-AEMPS Approvals